Findings represent the fifth COVID-19 tracking report in a series focused on reaching the voice of US frontline treating physicians, conducted and sourced last week by InCrowd, a provider of real-time primary market intelligence for the life science industry.
InCrowd's new research examined the perspectives of frontline-treating physicians in 25 newly reopened states, including their thoughts on their treating facilities' preparedness for an influx of patients that could result from reopening the state.
The study also asked their thoughts on scaling back social distancing, opening-up businesses, and managing future outbreaks.
Physicians are split on state readiness to reopen, with 41% believing yes, their state is ready to reopen, and 59% saying no, their state is not.
The majority of physicians with limited numbers of COVID-19 patients (fewer than 20), were in favor of reopening --compared to just 25% reported among physicians with 20 or more COVID-19 patients.
And when asked if they were in favor of beginning the process to open-up businesses and the economy, only 24% strongly agreed and 37% agreed overall.
InCrowd's data also show that masks and social distancing are important. Among physicians who believe their states are ready to reopen, nearly half wanted restrictions that coincide with opening, including required masking, 6-foot social distancing, and gathering/crowd limits.
For those physicians who do not believe their state is ready, one-third wanted a further downtrend in positive cases, and 23% wanted enforced mask-wearing, social distancing and gathering-size limits.
Testing remains an issue, particularly among US physicians who do not believe their state is ready to reopen.
Forty seven percent in this group wanted more widespread access and reliable testing before their state could safely reopen.
Among all respondents, about half report they are able to test all suspected COVID-19 cases, and just a third believe they have sufficient testing, staffing, and personal protective equipment to deal with potential outbreaks if occurred as a result of states re-openings.
Physician have personal concerns. Job security during the COVID-19 pandemic remains an issue for 40% respondents, down slightly from 45% noted in a national study of frontline-treating physicians fielded in April.
One-in-ten reported living separately from his or her family to ensure at-risk loved ones are protected from exposure to COVID-19.
A fraction reports an increasing volume of COVID-19 cases. When the survey fielded a week ago to physicians in states open or in the process of opening-up, only 22% of respondents reported that their facilities were experiencing increasing numbers of COVID-19.
InCrowd's COVID-19 reopening physicians' report included the perceptions of n=250 US physicians including emergency medicine and critical care specialists (n=180), hospitalists, and pulmonologists, each of whom is treating 10 or more unique patients for flu-like symptoms in any of the 25 states that had begun opening COVID-19-restricted services as of early May 2020.
InCrowd, a SARORAS company, is a life science developer of real-time, mobile-first, Micro-research solutions, empowering global 100 life science firms with fast, efficient, high-quality primary market insights.
InCrowd serves more than 500 brands.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA